Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results
Pfizer raised its full-year profit and revenue forecasts on Tuesday, driven by higher-than-expected third-quarter results. Strong demand for the recently acquired cancer drug Padcev and the blockbuster blood thinner Eliquis propelled the financial beat. The pharmaceutical company also tapped a company veteran as its new chief financial officer. This performance reflects the momentum of Pfizer's post-COVID comeback as the company bets heavily on cancer and weight-loss drugs for its post-pandemic second act.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Pfizer raised its full-year profit and revenue forecasts on Tuesday.
- ✓ Third-quarter results were driven by strong demand for the cancer drug Padcev and the blood thinner Eliquis.
- ✓ Pfizer tapped a company veteran as its new chief financial officer.
What changed
Pfizer updated its financial outlook by raising its full-year profit and revenue forecasts for 2026 based on third-quarter performance.
Live updates
-
Pfizer Raises 2026 Forecasts After Strong Q3 Results
Pfizer raised its full-year profit and revenue forecasts on Tuesday, driven by higher-than-expected third-quarter results. Strong demand for the recently acquired cancer drug Padcev and the blockbuster blood thinner Eliquis propelled the financial beat. The pharmaceutical company also tapped a company veteran as its new chief financial officer. This performance reflects the momentum of Pfizer's post-COVID comeback as the company bets heavily on cancer and weight-loss drugs for its post-pandemic second act.
Why it matters
The upward revision of forecasts highlights Pfizer's strategic pivot toward specialty products like oncology treatments following the decline of pandemic-era product sales. Strong performance from established blockbusters such as Eliquis combined with recent acquisitions provides a new growth engine for the firm. Leadership changes, including the appointment of a new chief financial officer, accompany this ongoing transition.
What is confirmed
- Pfizer raised its full-year profit and revenue forecasts on Tuesday.
- Third-quarter results were driven by strong demand for the cancer drug Padcev and the blood thinner Eliquis.
- Pfizer tapped a company veteran as its new chief financial officer.
What to watch next
- Execution and sales performance of newly acquired cancer and weight-loss drugs
- Impact of the new chief financial officer on corporate financial strategy
confidence 100%Sources used for this update (11)
- www.ctvnews.ca — U.S. midterms: Republicans shy away from Trump ahead of vote
- CNBC — Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
- Reuters — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat
- Barron's — Pfizer Bets on Cancer and Weight-Loss Drugs in Post-Pandemic Second Act
- Fierce Pharma — Pfizer delivers Q3 beat as post-COVID comeback gains momentum
- Yahoo Finance — Pfizer Reports Strong Third-Quarter 2026 Results And Raises 2026 Guidance
- www.aol.com — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results - AOL
- www.bnnbloomberg.ca — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive ...
- pharma.economictimes.indiatimes.com — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive ...
- www.biospace.com — Pfizer Reports Strong Third-Quarter 2026 Results And Raises ...
- bdnews24.com — Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive third-quarter results - Latest News
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community